Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03687632 · ClinicalTrials.gov registry record · Phase 2
ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects
A Phase 2 study, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT03687632 is a Phase 2 study that has completed, run by Noveome Biotherapeutics, formerly Stemnion. The registered enrollment target is 13 participants.
The verdict
NCT03687632, a Phase 2 study, has completed, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary aim of the study is to evaluate the clinical response of ST266 treated subjects with persistent corneal epithelial defects during 28 days of therapy. The secondary endpoint is the response rate within 14 days of treatment.
Interventions
- BIOLOGICAL ST266
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-06-10 |
| Est. Completion | 2020-08-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03687632
The ClinicalTrials.gov registry entry for NCT03687632 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noveome Biotherapeutics, formerly Stemnion, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ST266 is the first listed.
NCT03687632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03687632 about?
NCT03687632 is a clinical study titled "ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects". The primary aim of the study is to evaluate the clinical response of ST266 treated subjects with persistent corneal epithelial defects during 28 days of therapy. The secondary endpoint is the response rate within 14 days of treatment.
What is the current status of trial NCT03687632?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2019-06-10. Estimated completion is 2020-08-25.
What interventions are being tested in trial NCT03687632?
The interventions under investigation include: ST266 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03687632?
This trial is sponsored by Noveome Biotherapeutics, formerly Stemnion, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.